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Abstract: Human noroviruses are recognised as the major global cause of viral gastroenteritis. Here,
we provide an overview of notable advances in norovirus research and provide a short recap of the
novel model systems to which much of the recent progress is owed. Significant advances include
an updated classification system, the description of alternative virus-like protein morphologies and
capsid dynamics, and the further elucidation of the functions and roles of various viral proteins.
Important milestones include new insights into cell tropism, host and microbial attachment factors
and receptors, interactions with the cellular translational apparatus, and viral egress from cells.
Noroviruses have been detected in previously unrecognised hosts and detection itself is facilitated by
improved analytical techniques. New potential transmission routes and/or viral reservoirs have been
proposed. Recent in vivo and in vitro findings have added to the understanding of host immunity in
response to norovirus infection, and vaccine development has progressed to preclinical and even
clinical trial testing. Ongoing development of therapeutics includes promising direct-acting small
molecules and host-factor drugs.
Keywords: norovirus; phylogeny; genome; virion; replication; clinic; epidemiology; detection;
immunity; treatment and prophylaxis; evolution; model systems
1. Introduction
Human noroviruses (HuNoVs) are recognised as the leading global cause of sporadic
and epidemic viral gastroenteritis [1,2] and account for a global economic burden of
60 billion USD, over one million hospitalisations, and 219,000 deaths per annum [2,3].
Despite their importance, the fact that the understanding of HuNoV biology lags behind
that of other positive strand RNA viruses, is, in great part, due to the difficulties historically
associated with robust in vitro HuNoV propagation. In recent years, however, novel model
systems have provided new opportunities for study and previous knowledge gaps are
progressively being filled.
Last comprehensively reviewed in 2015 by Robilotti et al., [1], advances in the field in
the intervening six years cover nearly all aspects of norovirus biology. Here, we provide
an updated overview of norovirus phylogeny, genome organisation, virion morphology,
the replicative cycle, and clinical disease. Norovirus evolution, epidemiology, detection
and typing, immunity, as well as treatment and prophylaxis are discussed. We highlight
notable advances made in each of these subject areas and provide a recap of the novel
model systems to which much of the recent progress is owed.
2. Phylogeny—Past and Present
The Caliciviridae family, small, non-enveloped, positive sense, single-stranded RNA
viruses, derives its name from the Latin calix for chalice with reference to the cup-shaped
depressions that commonly contour the virion surface of caliciviruses. The family is
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comprised of eleven approved genera: Norovirus, Sapovirus, Nebovirus, Recovirus, Lagovirus,
Vesivirus, Valovirus, Bavovirus, Nacovirus, Minovirus, and Salovirus (Figure 1), which are
distinguished based on over 60% amino acid sequence difference in the complete major
capsid protein (VP1) sequence [3] and infect a wide range of host species causing a variety
of mainly species-specific diseases [4].
Figure 1. Schematic diagram of the Norovirus genus within the Caliciviridae family. The ten established
genera (GI—GX), as defined by Chhabra et al. 2019, are shown, as well as the species wherein each
genogroup has been detected.
The genetically diverse noroviruses, which infect a broad range of mammalian hosts,
derived their name from the city of Norwalk, Ohio, where an acute gastroenteritis outbreak
was caused by the prototypic Norwalk virus in 1968 [5]. In the early 2000s, classification
into norovirus genogroups and genotypes was initially based on amino acid sequence
analysis of the complete VP1 capsid protein, with an amino acid divergence of 14.1% within
a genotype and an adjusted cut-off threshold of a minimum of 15% pairwise difference
proposed for classification of new genotypes [6,7].
In 2013, the international Norovirus Classification Working Group put forth a proposal
for a unified norovirus nomenclature and genotyping, whereby noroviruses were geneti-
cally classified into six established genogroups (GI–GVI), with a seventh proposed (GVII).
Genogroups were further divided into at least 38 genotypes based on phylogenetic clus-
tering of complete VP1 amino acid sequences [8,9]. The GII.4 strains were additionally
subtyped into variants based both on phylogenetic clustering and on the condition of their
having become epidemic in at least two separate geographical locations and were named
according to year and location of the first full-length capsid sequence in the public domain.
To account for the common occurrence of recombination in the overlapping region between
the first two of three open reading frames (ORF1/2) encoded by noroviruses, a dual nomen-
clature system based on complete capsid sequences in ORF2 and partial sequences of the
RNA-dependent RNA polymerase (RdRp) region in ORF1 was established [8]. Naming of
“orphan” ORF1 polymerase types, also known as “obligatory norovirus recombinants” and
designating known RdRp sequences lacking attributed capsid sequences but promiscu-
ously associated with capsids of different genotypes, followed a preliminary alphabetical
naming system [8].
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Adhering to the established criteria for genotype attribution and numbering of com-
plete capsid sequences, the prior classification was recently updated to encompass ten
accepted genogroups (GI to GX) and 49 confirmed genotypes (Figure 1), as well as two ten-
tative genogroups (GNA1 and GNA2) and three proposed genotypes [10]. To more easily
accommodate ORF1/2 recombination of noroviruses and to eliminate the necessity of the
letter-based orphan ORF1 naming system, partial RdRp sequence clusters were grouped
into two tentative polymerase (P)-groups as well as 60 accepted and 14 tentative P-types
independently of the classification of their capsid genogroups or genotypes. Accordingly,
nine VP1 genotypes in GI, 26 in GII, three in GIII, two each in GIV, GV, and GVI, and one
each in GVII to GX are currently recognised; of the P-types, 14 cluster in GI, 37 in GII, two
in GIII, one in GIV, two each in GV and GVI, and one each in GVII and GX. The previous
dual typing nomenclature of norovirus strains was abandoned in favour of an updated
version first listing the capsid genotype followed by the P-type between brackets (e.g.,
previous designation GII.P12-GII.3 and current designation GII.3[P12]). For strains where
ORF2 and ORF1 amino acid sequences cluster in different genogroups, the designations are
Genogroup.genotype[Pgroup.P-type] (e.g., previous designation GVI.P1-GIV.2 and current
designation GIV.2[GVI.P1] [10].
Genogroups GI, GII, GIV, GVIII and GIX (previously GII.15) infect humans and cause
acute gastroenteritis [10,11]. Other species in which noroviruses have been detected include
pigs (GII) [12], cattle and sheep (GIII) [13–15], rats and mice (GV) [16], dogs (GVI) [17],
and bats (GX) [18]. Tentative new genogroups GNA1 and GNA2 are detected in harbour
porpoises [19] and sea lions [20], respectively.
3. Genome Organisation
The linear, positive sense, single-stranded RNA genomes of noroviruses are between
7.3 and 7.5 kilobases (kb) in length [21]. A subgenomic RNA identical to approximately the
last 2.3 kb of the genome is found in viral particles and is expressed, at higher levels than
the viral genomic RNA, in infected cells [22]. The 5′ ends of norovirus genomic and subge-
nomic RNA are linked to viral protein VPg [23–25], the 3′ ends are polyadenylated [26].
At their extremities, norovirus genomes contain short untranslated regions (UTRs) [27]
which contain evolutionarily conserved RNA secondary structures that extend into the
coding regions and are repeated throughout the genome, playing functional roles for viral
replication, translation, and pathogenesis by binding viral and host factors [28]; a highly
conserved non-coding RNA stem-loop structure upstream of the start site for subgenomic
RNA initiation at the overlap of ORFs 1 and 2 has been identified as the core promoter
for norovirus subgenomic RNA synthesis by binding with the viral RNA-dependent RNA
polymerase (RdRp) [21,29–31].
The norovirus genome is organised into three or, for MNV, four ORFs (Figure 2) [32].
The 5′ proximal ORF1 encodes a large polyprotein that is co- and post- translationally
cleaved by a virus-encoded protease into six nonstructural proteins (NS) involved in
replication complex formation (NS1/2, NS3, and NS4), genome linkage (NS5 and VPg),
polyprotein processing (NS6), and genome replication (NS7 and RdRp) [21,33,34]. ORF2
and ORF3, both translated from subgenomic RNA, encode the structural components of
the virion, major viral protein (VP1) and minor viral protein (VP2), respectively. ORF4,
unique to MNVs, overlaps ORF2 and is also translated primarily from subgenomic RNA; it
encodes the virulence factor 1 (VF1) which is involved in regulation of innate immunity
and apoptosis [32,35]. The functions of various norovirus proteins are discussed further
below in the context of the norovirus replicative cycle and were recently reviewed by
Campillay-Véliz et al. [36].
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Figure 2. Schematic diagram showing the organisation of norovirus genomes. (Above) The human
norovirus genome is covalently attached to genome-linked viral protein VPg at the 5′ end and
is polyadenlyated at the 3′ end. The genome is divided into three open reading frames (ORFs).
ORF1 is translated as a polyprotein, which is cleaved by the viral protease (Pro) to produce the
nonstructural proteins (p48, NTPase, p22, VPg, Pro, and Pol). ORF2 and ORF3 are translated from a
subgenomic RNA. They encode the major structural protein, VP1, and the minor structural protein,
VP2, respectively. The 5′ and 3′ genome extremities contain short untranslated regions (UTRs).
(Below) The murine norovirus shares a similar genome organisation but has an additional fourth
ORF, which overlaps with ORF2 and is also translated primarily from subgenomic RNA into the
virulence factor 1 (VF1) protein; adapted from Thorne and Goodfellow 2014 [21].
4. Virion Morphology
Typically, a norovirus capsid is 27–30 nm in diameter and exhibits T = 3 icosahedral
symmetry, with calicivirus, characteristic cup-like depressions localised at the three- and
five-fold symmetry axes. Each capsid is composed of 180 copies of monomeric major
structural protein VP1 which form 90 dimeric capsomers [37,38]. Each VP1 comprises a
short N-terminal arm of unknown function, a shell domain (S), and a protruding domain
(P) [38]. The well-conserved N-terminal S domain faces the interior of the capsid and forms
a continuous surface surrounding the viral RNA. The P domain, linked to the S domain
through a flexible hinge, corresponds to the C-terminal part of VP1. It is postulated to
confer increased stability to the icosahedral capsid and to provide a control for the size of
viral particles [39]. The P domain is further divided into a proximal P1 stalk subdomain at
the base of the arches and the highly variable distal P2 subdomain. Localised at the tips of
the arches, the exposed P2 subdomain interacts with neutralising antibodies and contains
the defined host receptor binding site for MNVs [40] and putative receptor binding site for
HuNoVs [41–44]. Cryo-electron microscopy has revealed distinct P domain conformations
for both MNV and certain HuNoV strains (GII.10) that are dependent on buffer pH and
the presence of bile salts. A “floating” P domain is described to hover above the shell in
physiological buffers but dynamically rotates and contracts onto the shell surface in the
presence of bile salts in a probable mechanism that enhances P domain stabilisation and
receptor affinity [45]. The unique flexibility of the Caliciviridae P domain in response to
environmental cues is described in the 2019 review by Smith and Smith [46], the role of bile
salts and their interactions with viral capsids (also further discussed below) were recently
reviewed by Tenge et al., 2021 [47]. Interestingly heterologous expression of larger GII.4
variant VLPs exhibiting T = 4 icosahedral symmetry (T = 4 particles assembled from 240
copies of VP1) was recently described [48].
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Minor structural protein VP2 [49], encoded by all caliciviruses, is located at the interior
of the viral capsid and bound to a conserved motif in the VP1 S domain. It is postulated
to be involved in MNV encapsidation via an interaction with viral genomic RNA [21,50]
and acidic regions of VP1 [33] and is held to regulate expression and stability of VP1 in
HuNoVs [27]. VP2 integrity has been shown to be essential for productive replication of
infectious feline calicivirus (FCV) [51]. Feline calicivirus VP2 forms a portal-like assembly
following host cell receptor engagement and has been hypothesised to function as a channel
for viral genome release from the endosome into the host cell cytoplasm [52]; morphological
changes upon viral entry may be a general phenomenon shared amongst all calicivirus
VP2s.
5. Replicative Cycle
5.1. Attachment, Receptor Engagement, Endocytosis, and Uncoating
As the initial step of the norovirus replicative cycle and decisive early determinant
of cell tropism, host range, and pathogenesis, the multi-phasic process of viral entry
commences via virion attachment to the cell surface [53]. Attachment of noroviruses is
mediated by binding of the virus to both cell-associated and soluble host factors [44].
HuNoVs are bound by histo-blood group antigens (HBGAs), as evidenced by in vitro
assays [54] as well as multiple volunteer studies documenting the correlation between
long-term resistance to infection with certain HuNoV strains and FUT2 gene-mediated
genetic polymorphisms that determine host secretor status [55,56]. The ability to secrete
a diverse set of fucosylated HBGAs into body fluids and to express HGBAs on mucosal
cells (secretor) is associated with HuNoV susceptibility. Expressing only a limited array
of HBGAs (non-secretors) is linked to resistance to certain HuNoV strains (including
genogroups GI.1 and prevalent GII.4) [57,58]. While non-secretors experience infections
with a lesser variety of norovirus strains, their resistance to HuNoV has recently been
shown not to be absolute and they can become infected by secretor-independent strains
(GII.3, GII.7, and GII.6), newly implicating non-HGBA ligands (fucosylated and sialylated
carbohydrates [59]) and co-factors in HuNoV binding [44,60,61]. While canine (GVI)
and bat (GX) noroviruses attach to HBGAs similar to HuNoVs [62,63], bovine GIII.2
strains do not bind the same carbohydrate moieties as HuNoVs but recognise α-Gal
1,3 motif [64–66]. For MNVs, non-essential carbohydrate attachment factors including
heparan sulfate proteoglycans and terminal sialic acid have been shown to enhance viral
VP1 binding in a strain-dependent manner [43,67,68]. Notably, sialic acids have also been
implicated in facilitating the attachment of bovine noroviruses and FCV to susceptible
cells [69,70].
Suggested host and microbial cofactors that enhance norovirus attachment to cells
(also in a strain-dependent manner) include bile acids (MNV and HuNoV) [47,71–73],
phospholipids (MNV) [74], and divalent cations (MNV) [71].
The second step of viral entry is the engagement of host receptors to actively promote
viral access to cells. CD300lf, an immunoglobulin domain-containing integral membrane
protein expressed in myeloid cells, lymphoid cells, and intestinal epithelial tuft cells [75],
has been identified as the primary physiologic cellular MNV receptor [43]. It functions
by binding the apical side of the P2 subdomain and is essential for infection of diverse
MNV strains both in vitro and in vivo, independent of infection route [40]. Its paralogue
CD300ld has also been demonstrated to be sufficient for MNV infection in vitro. Ectopic
expression of murine CD300lf on human and other mammalian cells has been shown to be
sufficient to confer cross-species susceptibility, effectually breaking the species barrier and
allowing MNV replication in non-murine cells [43]. Human CD300lf is not a receptor for
HuNoVs and the HuNoV receptor remains unknown [40].
The details of which mechanisms are involved in the endocytic internalisation of
HuNoV particles following receptor engagement are unknown. For MNVs, entry into
permissive macrophages and dendritic cells is known to be rapid, requiring host choles-
terol and dynamin [76,77]. This viral endocytosis is independent of pH [78], clathrin,
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and caveolae, and is neither mediated by phagocytosis nor micropinocytosis [76]. For
bovine noroviruses, VLP internalisation into permissive cells involves both the cholesterol-
dependent pathway and macropinocytosis [69]. Norovirus attachment and entry were
most recently reviewed in the 2019 publication by Graziano et al. [44]; norovirus, host, and
microbiota interactions were outlined by Walker and Baldridge the same year [79].
After endocytosis, endosomal escape and viral uncoating are required to release the
viral genome into the host cytoplasm. While the process remains unsolved for noroviruses,
a recent near-atomic resolution analysis of FCV yielded important basic information re-
garding these important last steps of calicivirus entry. In the process of clathrin- and
pH-dependent endocytosis, binding of FCV to its receptor feline junctional adhesion
molecule A was shown to induce formation of a portal-like assembly made up of twelve
copies of VP2 arranged with their hydrophobic N termini pointing away from the virion
surface around a pore in the capsid shell. The funnel-like structure is hypothesised to func-
tion as a channel for the delivery of the viral genome through the endosomal membrane
into the cytoplasm of a host cell, thereby initiating infection [52].
5.2. Translation and Polyprotein Processing
Following its release into the cytoplasm of a permissive cell, the VPg-linked norovirus
RNA acts as a messenger RNA (mRNA) template for an initial round of viral RNA transla-
tion. Attached covalently to the 5′ end of the genome, norovirus VPg (NS5) functions as a
cap substitute to recruit eukaryotic initiation factors and mediate translation of viral RNA
into protein via multiple direct interactions with the cellular translational apparatus of the
host cell and core stress granule components [23,80–84]. Interactions between various host
cell RNA-binding proteins and conserved RNA secondary structures of complementary se-
quences at the 3′ and 5′ genome extremities are further postulated to enhance and regulate
viral protein translation, putatively by stabilising sequence-mediated, long-range physical
RNA interactions that promote genome circularisation [28,85].
Translation of the viral proteins VP1 and VP2 is regulated by the 3’ terminus of
the polycistronic subgenomic RNA [27]. VP1 and VP2 translation occurs primarily from
the ORFs of the subgenomic RNA generated via premature termination and/or internal
initiation during RNA synthesis (see below). Following its transcription from genomic
RNA by the norovirus nonstructural proteins, subgenomic RNA is expressed at higher
levels than the viral genomic RNA in infected cells [22], in a probable strategy to augment
levels of VP1 production for virus assembly [21]. Translation of ORF4 in MNV from
subgenomic RNA yields VF1 which has been implicated in interfering with innate immune
signalling at the cellular level and was recently found to delay the upregulation of IFN-β
and other Interferon stimulated genes (ISGs) in vitro [32].
5.3. Viral Genome Replication
Once translated, the ORF1 polyprotein is co- and post-translationally cleaved by
the viral protease (NS6) to release NS precursors and mature viral proteins (NS1/2 to
NS7) [34,36,86], which then serve to assemble the replication complex by recruitment of
cellular membranes to the perinuclear region of the cell [87].
Murine norovirus NS1/2, the least conserved norovirus NS [33], is hypothesised to be
one of the main drivers of replication complex formation by associating with components
of the endocytic and secretory pathway together with co-localising NS4 [88,89]. NS1/2
contains an N-terminal disordered region and a C-terminal predicted transmembrane
domain [90]. Murine norovirus NS1/2 has been shown to induce rearrangement of the
endoplasmic reticulum. It is implicated in viral persistence in vivo [91] and, once un-
conventionally secreted via caspase-3 cleavage, is essential for intestinal pathogenesis of
MNV infection and resistance to endogenous IFN-γ [92]. Its HuNoV equivalent (p48)
promotes Golgi disassembly dependent upon the C-terminal hydrophobic region and
disrupts expression and trafficking of cell surface proteins by interfering with cellular
vesicle transport [93,94]. A secreted form of HuNoV NS1 is also observed [92].
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As a constituent of the MNV replication complex, NS4 localises to endosomes [87,88].
HuNoV NS4 (P22) has been shown to induce Golgi disassembly [95] and has been identified
as a key determinant in the formation of membrane alterations by HuNoVs [94]. MNV
and HuNoV NS4 both inhibit cellular protein secretion (mildly in MNV and potently in
HuNoV) [88,95].
While NS1/2 and NS4 are acknowledged to be key main mediators of replication
complex formation, NS3, to which RNA chaperon and helicase activities have been at-
tributed [96,97], has also been shown to localise to cellular membranes [87]. HuNoV and
MNV NS3 both induce formation of motile membrane-derived vesicular structures that
colocalise with the Golgi apparatus and the endoplasmic reticulum [94,98].
Norovirus genome replication occurs via a negative-strand intermediate [21]; sub-
sequent to the initial round of translation of the incoming parental positive-strand RNA,
this mRNA serves as a template for the synthesis of negative-strand RNA from its 3′
end and the formation of a double-stranded replicative form. Then, the negative-sense
genomic and subgenomic RNAs are used as templates for the synthesis of positive sense
genomic and subgenomic RNAs [21]. These transcription reactions are catalysed by the
RNA-dependent RNA-polymerase (RdRp, NS7), using de novo mechanisms for synthesis
of negative-stranded RNA [99,100], and VPg-dependent mechanisms of positive sense
genomic and subgenomic RNA synthesis in which the NS7 uses multifunctional VPg as a
proteinaceous primer [23,25,101]. Multifunctional VPg [24] plays various roles in norovirus
replication including induction of higher-order RdRp multimer or tubular fibril formation
and enhancement of MNV RdRp activity [25]. Furthermore, induction of a G0/G1 cell
cycle arrest which provides a favourable environment for viral replication (the cellular
growth phase provides high levels of ribonucleotides and a high translation efficiency) has
been demonstrated to be a conserved function of norovirus VPgs [101]. Two, not mutu-
ally exclusive, models have been proposed for the generation of norovirus subgenomic
RNA. On the basis of the detection of negative-sense subgenomic RNA copies in Norwalk
virus replicon-bearing and MNV infected cells [29,102], the premature termination model
proposes synthesis of negative-sense subgenomic RNA linked to an unidentified termi-
nation signal, and subsequent generation of positive sense subgenomic RNA from this
template. The internal initiation model postulates that the highly conserved stem-loop
structure upstream of the subgenomic start site in the negative-sense genomic RNA acts
as the core of an internal subgenomic promoter and binds to the RdRp to direct initiation
at the overlap of ORFs 1 and 2. In this case, newly synthesised subgenomic RNA may
function as a template for further rounds of replication via a negative-sense subgenomic
RNA intermediate [28–31].
5.4. Assembly and Exit
Self-assembly of VP1 into VLPs that are morphologically and antigenically comparable
to native virions [39] suggests that VP1 alone may be able to drive assembly of infectious
norovirus particles. While not essential for assembly, the 3′ UTR of the Norwalk mRNA
can stimulate VP1 expression via putative RNA-capsid interactions and the presence of
VP2 is held to enhance the stability of nascent particles [27,103,104]. Associated with a
conserved acidic motif in the VP1 S domain at the capsid interior [33,50], the highly basic
VP2 may provide the link between capsid subunits and acidic viral RNA [21,50].
Upon completed assembly, virion exit is the last step of the replicative cycle. Active
viral replication of MNVs in permissive cells, and indeed the expression of the MNV
polyprotein alone, has been shown to regulate and induce apoptosis and programmed
cell death in conjunction with downregulation of prosurvival factor survivin in infected
cells [105,106]. While its role in viral exit remains undetermined, inhibition of apoptosis
has been shown to accelerate cell death, change the death pathway to rapid necrosis, and
to ultimately result in an over 10-fold reduction in infectious norovirus yield [107].
While MNVs lytically infect innate immune cells including macrophages and dendritic
cells in vitro [16], the nature of in vitro B cell infection by HuNoVs and MNVs is distinct,
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since mature B cells are infected non-cytopathically [108,109], suggesting that different
mechanisms of cellular regulation and cell exit can be employed by noroviruses. The
paradigm that nonenveloped viruses must lyse their target cells in order for progeny
virions to be released extracellularly has further been challenged by the discovery that,
amongst other enteric viruses, noroviruses can be secreted from cultured cells inside
extracellular membrane-bound vesicles and that they are shed in faeces within vesicles
of exosomal or plasma membrane origin presenting highly virulent units of faecal-oral
transmission [110]. An outline of the entire norovirus replication cycle is provided in
Figure 3.
Figure 3. Outline of the norovirus replication cycle. Human and murine noroviruses (turquoise
hexagons) attach to the cell surface using carbohydrate attachment factors and cofactors (1). To
mediate entry, binding to a protein receptor is required (2). After entry (3) and uncoating (4),
the incoming viral genome is translated through interactions with genome-linked protein VPg
(nonstructural protein NS5, red triangle) at the 5′ end of the genome and the cellular translation
machinery (5). The open-reading frame 1 polyprotein is co- and post-translationally cleaved by the
viral protease (NS6, blue flash) (6). The replication complex is formed by recruitment of cellular
membranes to the perinuclear region of the cell, through interactions with NS1/2 (rose shape) and
NS4 (yellow shape) (7). Genome replication occurs via a negative-strand intermediate (dashed line)
(8), and genomic and subgenomic RNA (unbroken lines) are generated by the viral RNA-dependent
RNA polymerase (NS7, green jagged circle), using de novo and VPg- or internal promoter-dependent
mechanisms (9). Replicated genomes are translated or packaged into the capsid (in the case of
whole-length genomes), composed mainly of viral protein 1 (VP1), for virion assembly (10) and exit
(11).
6. Clinical Aspects of Norovirus Infection
6.1. Human Noroviruses
Human noroviruses cause both sporadic and epidemic viral gastroenteritis [1,111].
After a short incubation period of 24–48 h [112], clinical symptoms typically last for two
to three days [1], followed by a median of four weeks of post-clinical shedding [113] with
peak viral titres varying between 105 and 109 genome copies/g of faeces [114]. Characteris-
tic symptoms of HuNoV infection are acute onset of watery, non-bloody diarrhoea, and
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projectile vomiting [115]. Other symptoms include abdominal cramps, nausea, bloating,
mild fever, chills, headaches, and myalgia [116–118]. While self-limiting gastrointestinal
infections are the norm, more severe intestinal pathologies such as necrotising enterocolitis
in neonates [119,120], post-infectious irritable bowel syndrome [121], and exacerbation of
inflammatory bowel disease [122] have been described. Atypical extraintestinal patholo-
gies such as seizures in young children [123–125], encephalopathy [126], and acute liver
dysfunction [127,128] have also been reported in association with norovirus infections.
Norovirus RNA has been detected in sera [129] and cerebrospinal fluids [126] of infected
individuals, suggesting possible spread to peripheral tissues.
Despite typically eliciting severe gastroenteritis, HuNoVs cause only modest intestinal
pathologies. Histopathological changes in the small intestine include broadening and
shortening of the microvilli, crypt hypertrophy, as well as increased epithelial mitoses
and apoptosis [130]. Decreased brush border enzyme activity; transient malabsorption
of D-xylose, fat, and lactose; disruption of epithelial barrier functions; reduction of tight
junctional sealing proteins; and stimulation of active anion secretion suggest that both a
leak flux and alterations of secretory and/or absorptive processes cause HuNoV-induced
diarrhoea [131–133]. Vomiting episodes may be linked to abnormal gastric motor functions
and delays in gastric emptying, however, the underlying pathophysiology remains un-
clear [134]. Asymptomatic infections and viral shedding similar to that of symptomatic
infections [114] have been both experimentally observed in volunteer studies [135] and de-
tected in various epidemiological analyses of clinically healthy individuals and those with
various underlying illnesses resulting in impaired immunity [136–139]. Customarily, an
acute and self-limiting illness, HuNoV infection can become persistent in the elderly [140],
malnourished, and/or immunocompromised (individuals with genetic or acquired im-
mune deficiencies, cancer patients undergoing treatment, transplant patients) [141–145].
These individuals often experience severe, even lethal, persistent or recurring NoV in-
fections during which prolonged diarrhoea and vomiting can lead to weight loss and
malabsorption; in these patient cohorts, viral RNA remains detectable in stool samples for
months to years [141,146–148].
6.2. Animal Noroviruses
Animal noroviruses have been linked to gastroenteritis outbreaks and acute diar-
rhoeic episodes of varying severity in cattle [13], pigs [149–151], cats (including a captive
lion cub) [152,153], and dogs [154]. While a clinical association typically exists in these
domesticated mammalian hosts, asymptomatic infections have been observed (at lower
prevalences) in epidemiological screening studies [15,66,155]. The only documented GIII
sheep noroviruses were reportedly detected in animals that showed no obvious clinical
signs [156]. In wild animals such as bats [18], harbour porpoises [19], and Californian
sea lions [20], where noroviruses are typically detected in the context of metagenomics
analyses and/or retrospective analyses of stored samples, a potential disease association
often remains undetermined.
6.3. Murine Noroviruses
Murine noroviruses have been isolated from asymptomatic wild populations of both
field and wood mice (Apodemus agrarius and Apodemus sylvaticus) [157,158] and have been
detected in various cohorts of domesticated mice (Mus musculus), including mice sold as
pets or snake food, show animals, and those bred for academic research [158].
Indeed, MNVs are recognised as one of the most prevalent, albeit often undetected,
pathogens of contemporary laboratory mice, as evidenced by serologic testing and reverse
transcription polymerase chain reaction (RT PCR) screening [159–161]. Thirty fully se-
quenced MNV strains have been isolated from specific-pathogen-free mice in academic
research colonies across the globe; while these strains comprise a single genetic cluster, they
broadly segregate into two categories regarding their pathogenesis and disease profile [162].
The prototype acute strain MNV-1, which infects immune cells in the gut-associated lym-
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phoid tissue, reaches peak intestinal titres 1–2 days post-infection (dpi) and is cleared by
7–14 dpi. Persistent strains MNV-3 and MNV-CR6 can establish life-long infections, linked
to replication in the caecum, colon, mesenteric lymph nodes, and rare intestinal epithelial
tuft cells [161,163,164]. Persistent asymptomatic infection with typically nonpersistent
strain MNV-1 CW3 has been associated with adaptive changes to viral proteins NS1/2,
NS7, and VP2 [91,165].
Notwithstanding differences in clearance kinetics and cell tropism, all MNV strains
elicit subclinical infections of the intestine, lacking any association with diarrhoea or other
overt disease in wild-type juvenile and adult mice, and certain knockout, strains. A MNV-
1-induced decrease in faecal consistency as measured by visual scoring of faecal samples
of immunocompetent mice remains the only modest disease association (MNV-3 failed
to induce this pathology) [162]. Despite a subclinical presentation, quantifiable intestinal
pathology and detection of viral RNA in the liver, spleen, mesenteric lymph nodes, and
proximal intestine (but not in the lung, brain, blood, or faeces) have been described in
association with experimental MNV infection of wild-type hosts [16,160,166,167].
In severely immunodeficient adult mice lacking functional components of the innate
immune system and interferon pathways, MNV infection has been shown to be associated
with lethal disease [16,167]. Following oral MNV-1 inoculation, mice deficient in signal
transducer and activator of transcription 1 (STAT1) and recombination-activating gene 2
(RAG2) rapidly succumb to systemic disease associated with severe weight loss, diarrhoea,
bloating, pathologies in intestinal and peripheral tissues, and the presence of viral RNA
in all organs. Persistent strains MNV-3 and MNV-CR6 cause less overt symptoms than
MNV-1 in interferon-deficient mice [168].
Recently, self-resolving diarrhoea in the absence of systemic disease was reported in
MNV-infected wild-type neonatal mice, mirroring key clinical features of HuNoV disease;
diarrhoeic episodes were neither associated with disruption of the intestinal epithelium
nor notable inflammation. Oral MNV-1 inoculation, and to a lesser extent that of MNV-3
and MNV-CR6, caused acute diarrhoea in three-day-old BALB/c mice [169].
7. Human Norovirus Epidemiology and Transmission
7.1. The Societal Burden of Norovirus Infections and the Role of Genotype GII.4
As major aetiologic agents of global sporadic and epidemic non-bacterial gastroen-
teritis [1,111], HuNoVs cause significant morbidity and mortality in developing countries
and engender enormous economic losses in developed countries [170]. Causing a median
number of 669 million illnesses and an estimated 219,000 deaths across all ages per year
globally, HuNoVs have been calculated to result in a yearly total of 4.2 billion USD in direct
health care costs (outpatient visits and hospitalisation) and 60.3 billion USD in societal
costs (productivity losses due to absenteeism or mortality) [170].
GII.4 infections, which are responsible for the majority of past HuNoV outbreaks
(55–85%) and also sporadic cases, have been associated with a higher probability of severe
outcomes and lead to higher hospitalisation and mortality rates [171]. GII.4 noroviruses
have been the predominant genotype circulating in humans for over two decades. Until
2012, novel circulating GII.4 strains emerged every two to three years and replaced their
predecessors in an immune-driven selection process [172–174]. Since 2012, the same capsid
type, GII.4 Sydney, has been the dominant genotype [175,176]. Postulated mediators for the
GII.4 dominance include selective advantages and improved adaptation to host receptors
via physicochemical P2 changes in the virion of new GII.4 subtypes and the evasion of
herd immunity against predominant genotypes [177–180]. The elevated number of novel
nonsynonymous mutations in GII.4 capsid sequences and changing HBGA binding pat-
terns [181], as well as intragenotypic recombination have long been postulated to be a
driving force of GII.4 noroviruses. Strain-dependent differences in norovirus molecular
evolution via the accumulation point mutations are briefly discussed below. Complex
patterns of recombination within the GII.4 lineage were recently discussed in our 2018
review on norovirus recombination [182]. The position of the rapidly evolving dominant
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GII.4 variants has only recently been challenged by emergence and re-emergence of differ-
ent intra- and intergenotype recombinants modifying long-term global norovirus genetic
diversity trends [11,180,183–187].
7.2. Norovirus Shedding and Human Infectious Dose
Norovirus particles are shed by healthy individuals for a median of seven days [113].
In patients with waning immunity, long shedding can occur for weeks to months (in rare
cases even years) via the faeces or vomit of both infected symptomatic and asymptomatic
patients [139,188,189]. Almost half of all symptomatic individuals in long-term care facili-
ties were recently shown to shed norovirus for at least 21 days [190], while a recent cohort
study of immunocompromised individuals identified a proportion of chronic shedders
(16.4%) that shed infectious virus for 37 to > 418 days [189]. While the main norovirus
transmission route is faecal-oral transmission, with faecal loads reaching up to 109 genomic
copies/g faeces [113,114], transmission via vomiting has also been identified as a risk [191].
Unlike shedding through stool, vomiting is more likely to result in significant environmen-
tal contamination, leading to transmission through fomites and airborne vomitus droplets
(1.7 × 108 genome equivalent copies are typically shed in emesis (circa 4 x 104 genomic
equivalent copies/mL vomitus) [192–194]. The high doses of virus shedding stand in clear
contrast to the low 50% human infectious dose which has been calculated to lie between
1320 and 2800 genome equivalents [194].
7.3. Transmission Routes
Highly tenacious and resistant in the face of various virucidal treatments and decon-
tamination methods [195–197], HuNoVs are transmitted either via direct person-to-person
contact or by consumption of contaminated water or food (Figure 4) [198]. Infectious
viruses can enter environmental waters either via direct discharge or release of improp-
erly treated sewage from industrial-scale or small private wastewater treatment plants,
discharges from vessels, as well as urban runoff, the latter especially in times of flooding
or heavy rainfall which have been linked to a high prevalence of HuNoVs in coastal wa-
ters [199–202]. Suspended or precipitated noroviruses have been shown to retain infectivity
for weeks to months [200,203–205] and have been detected up to 10 km distant from their
discharge point [202,206].
The foodborne proportion of HuNoV outbreaks is estimated at 14% [198]. Foods im-
plicated in outbreaks are contaminated either directly with faecal matter at the source or by
infectious food handlers [207]. The most common food vehicles remain fresh or frozen soft
fruits and vegetables, ready-to-eat foods (such as sandwiches and salads [208–210]) which
require handling but no or little subsequent cooking, and undercooked or raw seafood
(bivalve molluscs) [211]. Bivalve molluscs, including cockles, mussels, clams, scallops,
and oysters, accumulate noroviruses via filter feeding; depuration practices, which aim
at eliminating such bioaccumulated pathogen charges, are unsuccessful in the face of
norovirus contamination. Increasingly, this effect is attributed to the fact that noroviruses
are not only filtered and concentrated through nonspecific interactions, but are also bound
in a genogroup- and strain-dependent manner to molluscan gastrointestinal carbohydrate
structures (HBGA-like moieties and sialic acid-residues) [60]. As known “hotspots” for the
accumulation of multiple norovirus strains [212,213], bivalve molluscs have been postu-
lated to present opportunities for infectious HuNoV inter-and intragenotype co-infection
(thus facilitating subsequent viral recombination within the host), and have been pin-
pointed as high-risk vectors for the introduction of novel recombinant strains into the
human population [182,214]. In a similar context, bivalve molluscs, as potential interfaces
of shared species exposure through filtration of human and animal waste, have also tenta-
tively been implicated as a putative way of introducing both human and different animal
noroviruses into a single host [182,215]. Norovirus outbreaks are often reported in the con-
text of communal dining at restaurants, festivals, picnics, schools, cruise ships and military
bases [216–219] or in institutional settings such as hospitals and care homes, where spread
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of infection from a common-source exposure is facilitated by enclosed living quarters
and reduced personal hygiene [146,220–222]. In the context of PPE donning and doffing
(this particularly in the context of the ongoing coronavirus pandemic), contamination of
healthcare personnel, but particularly untrained users, with tenacious oral or respiratory
pathogens that may contaminate masks or respirators has become a concern [196,197].
Figure 4. Norovirus transmission. Transmission routes of human noroviruses (solid arrows) and
animal noroviruses (dashed arrows) are shown. Unconfirmed transmission is indicated by a question
mark. The dashed arrow indicating transmission between domestic/wild animals denotes species-
specific transmission; the question mark accompanying it indicates putative interspecies transmission.
Adapted from Mathijs et al., 2012 [220] and Ludwig-Begall et al., 2018 [182].
Recently, wild birds and rodents were named as new potential HuNoV transmission
routes; GI and GII HuNoV genome copies were detected in faecal samples of gulls and
crows (31%) and rats (2%), albeit with high ct values, implicating them as possible mechan-
ical carriers, capable of spreading HuNoVs in the environment and possibly transmitting
the virus to humans directly or indirectly by contaminating foods [223]. Determination of
the replication capability of HuNoVs in these new tentative carriers (e.g., by detection of
viral antibodies in blood or whole virus particles in faeces) is still pending. The high ct
values suggest a possible mismatch between GI/II primers and probes, suggesting that the
detected viruses might more feasibly be gull- and crow-specific avian noroviruses.
7.4. Seasonality of Human Norovirus Infections
Human norovirus infections follow a typical seasonality with incidents peaking during
the winter months from October to March in the northern hemisphere [224]. While not
fully elucidated, this pattern is attributed to a complex combination of host, climactic
environmental, and viral factors. On the host side, peaks in norovirus infections are linked
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to changes in societal behaviour, an upsurge in hospitalisations due to other infectious
diseases, and fading herd immunity. Inverse linear associations of norovirus laboratory
reports and daily temperatures have been reported, linking cold, dry conditions to higher
norovirus activity. Norovirus levels typically peak in northern winters in sewage [225,226],
freshwater [227,228], and seawater as conditions for norovirus persistence in waters are
improved by colder water temperatures and reduced solar irradiation [224,225,229].
7.5. Reservoirs
The excretion of infectious norovirus from persistently infected individuals [114,189]
is purported to be one of the sources of norovirus outbreaks. Not only has the involvement
of chronic shedders in hospital outbreaks indicated them to be a reservoir for nosocomial
transmission of noroviruses [146], but persistently infected patients have also been sug-
gested to contribute to HuNoV transmission as reservoirs for emerging strains. Intra-host
evolution via point mutation accumulation [230,231] and the acquisition of superinfections
over the protracted period of persistent infections [143] implicate persistently infected pa-
tient cohorts as potential reservoirs for novel HuNoV variants [213]. Multiple phylogenetic
analyses have identified viral populations in persistently infected patients to be highly
diverse and genetically distinct from viruses circulating in the general population [147,232].
The within-host viral variation via the acquisition of point mutations in chronic shedders is
typically not random but has been shown to be a result of positive selection, as evidenced
both by nonsynonymous versus synonymous substitution ratios (>1) and the clustering of
amino acid changes at VP1 blocking epitopes (hypervariable P2 domain) and HBGA bind-
ing sites on the capsid surface [139,230,231,233,234]. Indeed, the intra-host emergence of
antigenically distinct strains comparable to the variation between chronologically predomi-
nant GII.4 strains has been observed, suggesting that in certain individuals the evolution
during a persistent norovirus infection translates into relevant phenotypic variability, thus,
potentially selecting for viruses able to escape herd immunity to earlier isolates [235]. At an
average of five to nine mutations per 100 days [231] or 1.85 to 2.66 × 10−2 substitutions per
nucleotide site per year (s/n/y) in the viral capsid gene [234], norovirus evolution rates in
immunocompromised hosts are generally significantly elevated as compared with those
in healthy hosts. The process, whereby norovirus strains can acquire enough mutations
to constitute novel epidemic subtypes within weeks to months (on a global scale this
would normally take years), has been attributed to the particularities of a reduced but
constant intra-individual selection pressure in immunocompromised hosts [139,231,236].
Siebenga et al. reported that the number of VP1 amino acid changes selected per time in
intra-individual quasispecies was higher in patients with intermediate immunocompro-
mise than in severely immunocompromised patients [139]. Over the prolonged period of
persistent norovirus infections, superinfections with a second genotype have been shown
to occur in a sixth of patients; in such cases, temporary mixed infections can be detected
in a single sample [143]. Mixtures of norovirus strains further heighten the complexity of
intra-individual quasispecies in immunocompromised hosts and provide opportunities for
viral recombination, constituting another possible factor towards driving the emergence of
new epidemic strains [182,237].
While multiple analyses have highlighted the diversity of norovirus variants in im-
munocompromised patients and have shown that chronic variants have the propensity to
rapidly generate novel variants, the contribution of this diversity to norovirus evolution
at the inter-host population level is still unclear. Recent mathematical modelling based
on the standard epidemiological categorisation of susceptible, infected, and recovered
individuals, suggested that despite the capacity of immunocompromised hosts to generate
significant diversity, the relative isolation and rarity of such hosts limits their impact on
broader pathogen evolution and epidemiology. Specifically, only a minor role for immuno-
compromised individuals in shaping large scale evolutionary patterns and processes and
the global emergence of new HuNoVs was inferred [238].
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While the reservoir of novel norovirus strains is yet to be definitively identified,
norovirus diversity could also be originated at inter- and intra-host levels in otherwise
healthy populations of different age groups (from infants in day care centres [239] to adults
in the context of communal living and dining, as described above). Thus, mutations could
arise during transmission events which present an evolutionary bottleneck in outbreak
settings, and/or during shedding in healthy individuals [232,237].
The lack of certitude regarding the source of newly emerging HuNoVs and the close
genetic relatedness between certain animal and human norovirus have generated interest
in the possible role of animals as a potential zoonotic reservoir for emerging strains [66].
More than two thirds of human emerging infectious diseases are thought to originate
from animal reservoirs [240]; for other members of the Caliciviridae family, interspecies
transmission has been reported [241,242]. The, as yet, unproven existence of a zoonotic
potential for noroviruses has long been discussed, the potential interfaces of shared species
exposure being food, water, or animal contact. Despite known noroviruses exhibiting
marked host specificity, the discussion about interspecies and/or zoonotic transmission is
fuelled by the close relationship of certain animal and human norovirus strains, detection
of HuNoVs in animal faeces, detection of antibodies against HuNoVs in swine, and the
demonstration of experimental HuNoV GII infection in gnotobiotic pigs [15,220,243,244].
Questions concerning species barrier determinants preventing HuNoV infection of murine
cells were recently resolved with the identification of a CD300lf proteinaceous receptor
as the primary determinant of MNV species tropism. All other components of cellular
machinery required for norovirus replication are conserved between humans and mice [43];
expression of MNV CD300 family receptor molecules rendered non-murine mammalian
cells susceptible to MNV infection [245]. If the key to cross-species transmission lies only
at a structural virus-host receptor level, this presents ORF1/2 norovirus recombination
(discussed in [182]), by which a nascent recombinant virus gains a complete novel capsid
protein set, in an interesting light, in that a “lucky” intragenogroup recombination event
between two co-infecting viruses might tender a zoonotic/interspecies recombinant. In-
deed, putative GIV.2_GVI.1interspecies recombinant FNoVM49, detected in a cat captured
near a Japanese oyster farm in 2015 [215], may have originated via a similar mechanism.
However, since conclusive data supporting inter-species transmission is yet lacking, the
continuous emergence of new HuNoV through zoonotic events is unlikely.
8. Detection and Typing of Noroviruses
8.1. Diagnostic Methods
Since norovirus infections present a major public health issue, rapid diagnosis is vital
for the initiation of appropriate control measures to curtail viral spread and curb the extent
of outbreaks. According to the typical clinical presentation of norovirus infections, the Ka-
plan criteria can assist in diagnosis when laboratory resources are unavailable to determine
an outbreak aetiology. Developed from pooled data of gastroenteritis outbreaks between
1967 and 1980, the Kaplan criteria consist of four patterns that characterise norovirus
outbreaks. Accordingly, stool cultures negative for bacterial pathogens, mean (or median)
duration of illness of 12–60 h, vomiting in greater than or equal to 50% of cases, and a
mean (or median) incubation period of 24–48 h satisfy the criteria for a Norwalk-like
infection [115]. While a useful diagnostic aid in discriminating confirmed foodborne gas-
troenteritis outbreaks due to noroviruses from those due to bacteria with a reportedly high
specificity (99%), these criteria are only moderately sensitive (68%) [246], necessitating
further laboratory confirmation of the viral aetiology.
Electron microscopy, utilised for the first ever identification of norovirus particles in
stool [5], permits rapid and direct visualisation of noroviruses, however, lacks sensitivity
and facile implementation (highly trained personnel is a prerequisite to its use), rendering
it ineligible for routine diagnostics [9]. In lieu of this costly method, and in the absence of
a stable and inexpensive HuNoV cell culture system, routine laboratory diagnostics for
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noroviruses are typically either performed via immunological assays or amplification of
viral nucleic acids.
While the development of a broadly reactive norovirus antigen enzyme immunoas-
say (EIA) has proven challenging owing to the number of antigenically distinct HuNoV
genotypes and the continuous antigenic drift of certain strains [247], several EIAs are
commercially available for the detection of GI and GII antigens in stool specimens. Most
commercial kits consist of solid-phase, sandwich-type immunoassays and include com-
binations of multiple cross-reactive monoclonal and polyclonal antibodies. Sensitivity
and specificity of these kits, typically around 70% and 90%, respectively, are subject to
significant variation depending on the viral load and norovirus genotypes present in the
sample. The clinical context of sample collection (sporadic case versus outbreak) and the
number of samples tested are recognised to influence the sensitivity of EIAs to such an
extent that their use, while undoubted for rapid screening of multiple faecal samples during
an outbreak of acute gastroenteritis, is not recommended in interpreting test results from
sporadic cases and that negative results should be further confirmed by molecular methods
(RT-PCR) [248,249]. Similarly, immunochromatographic lateral flow assays, designed for
rapid and uncomplicated testing of individual faecal samples, have been shown to have a
varying, genogroup-dependent sensitivity and, while useful for preliminary screening in
outbreaks, their negative results should be verified by RT-PCR [250].
Amplification-based techniques for the detection of noroviruses in clinical samples,
environmental samples, and food and water include conventional RT-PCR [251] and one-
or two-step quantitative real-time RT-PCRs (RT-qPCR) [252]. Most contemporary assays
use genogroup-specific oligonucleotide primers and fluorescent probes typically target-
ing a small conserved genome region at the ORF1/ORF2 junction [253]. Increasingly,
such assays are multiplexed, allowing simultaneous detection of multiple norovirus geno-
types within different genogroups, for example, the simultaneous detection of GI and GII
strains [254,255] or GI, GII, and GIV strains [256]; several different multiplex molecular
gastrointestinal diagnostic pathogen platforms are commercially available [257].
Quantitative RT qPCR assays, which implement either intercalating dyes [258], or
fluorescent probe-based chemistries [256], can be used to determine the amount of nucleic
acid in a sample. However, a distinction between infectious and non-infectious virus
particles is not possible and virus detection by RT-qPCR does not necessarily correlate
with a true infectious norovirus burden. Methods to evaluate the correlation between
genomic copies and infective norovirus particles are under investigation. Amongst these,
the binding long-range PCR [259] has been proposed to assess genome integrity and
both the use of a ligand binding step prior to RT-qPCR [260,261] or viability PCR assays
which include pretreatment with intercalating dyes are increasingly utilised to investigate
capsid integrity [262,263]. Comparison of RT-qPCR results with newly developed HuNoV
infectivity assays (further discussed below) may help determine cycle threshold cut-offs
for clinical diagnostic RT-qPCRs, allowing estimation of infectious virus burdens to help
guide infection control [264,265].
Increasingly, the spectrum of analytical techniques is being widened. Promising
developments in the field include biosensors (such as monoclonal antibodies, aptamers,
porcine gastric mucin, and HBGAs), investigated for their potential of concentrating
noroviruses, microarray-based assays [266] and omics-based analyses [267,268].
8.2. Genotyping
With the increasing implementation of molecular methods in norovirus diagnostics,
virus typing through (partial) sequence analysis has become increasingly common. The
web-based, open access Norovirus Automated Genotyping Tool (Version 2.0, NoroNet,
Bilthoven, The Netherlands) for sequence-based typing, available online from the NoroNet
website of the Dutch National Institute for Public Health and the Environment (http:
//www.rivm.nl/mpf/norovirus/typingtool; accessed on 01.06.2021), provides direct and
internationally standardised genotyping of noroviruses. On the basis of genetic homology
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and phylogenetic inferences, the tool assigns sequences to a norovirus genogroup, maps
query sequences to a specific location on the reference genome(s) and offers information
on RdRp- and capsid affiliation on either side of the ORF1/2 overlap. Briefly, the tool,
updated periodically with new names and reference strains, employs a typing algorithm
on ORF1 and ORF2 sequences of GI and II noroviruses, starting with BLAST analysis of
the query sequence against a reference set of Caliciviridae sequences. This is followed by
phylogenetic analysis of the query sequence and a subset of the reference sequences to
assign norovirus genotype and/or variant (GII.4), with profile alignment, construction of
phylogenetic trees, and bootstrap validation [269]. The Human Calicivirus Typing Tool
(HuCaT) (https://norovirus.ng.philab.cdc.gov/bctyping.html; accessed on 01.06.2021)
uses a set of curated reference sequences (identical to those of the NoroNet tool) that
are compared to query sequences using a k-mer- (DNA substring) based algorithm and
accurately assigns genotypes to queries [270]. For more detailed information of norovirus
detection and typing, we refer to the 2020 survey of analytical techniques for noroviruses
by Liu et al. [268] and the 2021 description of HuCaT by Tatusov et al. [270].
9. Immunity to Human Noroviruses
Many gaps remain in the understanding of natural immunity to HuNoVs. In addition
to genetic resistance to infection based on secretor status (see above), with non-secretors
representing as much as 20% of the European population [271], norovirus infection has
been shown to result in development of clinical immunity. Immunity against HuNoV is
postulated to include both cellular and humoral responses. Recent findings show that nat-
ural HuNoV infection results in the production of proinflammatory and anti-inflammatory
cytokines [272], that HuNoV replication in zebrafish larvae results in a measurable innate
response [273], and that the innate immune response partially restricts HuNoV replica-
tion in human intestinal epithelial cells (IECs) through interferon-induced transcriptional
responses and production of proinflammatory and anti-inflammatory cytokines [274].
Humoral immunity to HuNoV has been considered to be stronger and more long
lasting than cellular immunity. According to human challenge studies, first estimates of
immunity duration suggested short-term, adaptive immunity to homotypic Norwalk re-
challenge with high viral doses to last from two months to two years [275] or for longer than
six months [55]. Epidemiological data and mathematical modelling have since suggested
that naturally induced immunity in the absence of major strain changes may actually last for
much longer and potentially span up to a decade [276]. While seroprevalence studies have
shown an estimated 90% of adult populations to be seropositive to norovirus [277], probably
only a small fraction of the total HuNoV specific antibodies represent partial or even
absolute neutralising antibodies, i.e., correlates of protection that mediate reduced infection
or disease severity [278]. Strain dependent differences in the induction of protective
immune responses [279], antigenic diversity, and known lack of heterotypic cross-protection
between certain norovirus genogroups, genotypes, and strains [280] further confound the
determination of immunity duration [281].
In mice, the innate STAT-1-dependent immune response plays a key role in limiting
MNV replication [16], however, the initial innate response alone is often insufficient to
protect against acute MNV infection and humoral immunity has been shown to play a
critical role in MNV clearance [282] and protection from subsequent infection [279].
10. Treatment and Prophylaxis
Despite the clinical significance and societal burden of norovirus infections, neither
approved antivirals nor licensed vaccines are yet available.
10.1. Antivirals
While medical intervention is rarely needed in typical norovirus infections of immuno-
competent individuals, safe and effective antivirals are essential for treatment of high-risk,
persistently infected immunocompromised individuals, and other vulnerable populations
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(juvenile/elderly). In the absence of specific therapeutic measures, treatment is focused on
providing supportive care such as rehydration and electrolyte replenishment.
Research efforts towards antiviral development have been furthered by a deeper
understanding of the norovirus replicative cycle and recent breakthroughs in culturing
HuNoVs. Direct acting antiviral therapies target various stages of the norovirus replication
cycle [283,284]. Strategies to prevent norovirus attachment and entry include HBGA bind-
ing inhibition via various glycomimetic compounds [285–287] and passive immunotherapy
with monoclonal antibodies [288] or nanobodies [289]. The activity of NS6 protease in-
hibitors depends on preventing polyprotein processing by the viral NS6. Candidate drugs
targeting this step include broad-spectrum antivirals that covalently bind to the catalytic
site of 3C or 3C-like proteases [290], enzymatic transition state inhibitors, or analogues [291].
Compounds targeting viral polymerase NS7 to interfere with norovirus replication com-
prise chain-terminating and mutagenic nucleoside analogues as well as non-nucleoside
inhibitors. Nucleoside analogues under investigation include the cytidine analogue 2′-
C-methylcytidine [292] and its derivatives, and purine analogues favipiravir [293] and
ribavirin, the latter of which is licensed to treat chronic hepatitis C infections [145,294,295].
Modified C-nucleosides have been recently identified as viable starting scaffolds for further
optimisation of nucleoside-based inhibitors of norovirus replication [296]. Their inhibitory
effects are attributed to multiple modes of action including chain termination, provocation
of an error catastrophe scenario for the viral quasispecies via ambiguous base pairing (lethal
mutagenesis), direct RdRp inhibition, and unbalancing of intracellular NTP pools [297,298].
Non-nucleoside inhibitors target binding pockets of the RdRp, thus, preventing conforma-
tional changes required for formation of an active replication complex [299]. Host factor
drugs with the potential to treat norovirus infections include immunomodulators (type I, II,
and III interferons) [300–302] and small molecule inhibitors that downregulate viral RNA
secondary structure-binding host factors [284]. The thiazolide nitazoxanide, tested with
varying outcomes in preliminary clinical trials against chronic HuNoV infections [303,304],
may activate natural host antiviral defences but may also act through the direct inhibition
of virus protein production, maturation, and/or assembly. A comprehensive review of
progress made in the development of antivirals (this between 2010 and 2018) was provided
in 2018 by Netzler et al. [283].
10.2. Vaccines
The development of HuNoV vaccines is desired to protect vulnerable populations
(immunocompromised/juvenile/elderly) and high-risk groups, including health care
workers, military personnel, and (cruise ship) travellers experiencing crowding conditions.
Prophylactic applications may also include the vaccination of food handlers to reduce the
occurrence of foodborne outbreaks.
Key challenges for norovirus vaccine development pertain to vaccine effectiveness in
the face of norovirus strain diversity and continuing evolution, which call for multivalent
vaccines and periodic updates to protect against a range of current and emerging epidemio-
logically important genotypes. Furthermore, the lack of a universally accepted correlate of
protection against norovirus, documented varying seroresponse and uncertainty regarding
the duration of long-term immunity conferred by norovirus infection or vaccination are
barriers faced in norovirus vaccine development [305]. Nevertheless, a bivalent GI.1/GII.4
VLP vaccine [306] and a recombinant adenovirus vector vaccine expressing GI.1 or GII.4
VP1 with monovalent or bivalent dosing [307], are currently in clinical trials. Further
vaccines have been approved for clinical trial testing or are in the preclinical phase of de-
velopment [281,308]. Three recent reviews discuss challenges to and advances in HuNoV
vaccine development [281,305,308].
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11. Norovirus Evolution
The evolution of noroviruses is shaped both by the accumulation of point mutations
(genetic drift) and viral recombination (genetic shift), and the interplay of these two pivotal
evolutionary processes.
11.1. Human Norovirus Mutation Rates and Sources of Point Mutation
The norovirus RdRp, sharing functional and structural features with other RNA virus
polymerases, is the primary determinant of norovirus genetic diversity [309]. In vitro
RdRp fidelity assays have demonstrated overall HuNoV mutation rates to lie within the
range of those typically described for RNA viruses, but pinpointed strain-dependent
differences [310]. Globally predominant GII.4 strains had five- to 36-fold higher mutation
rates (average of 7.95 × 10−4 substitutions per nucleotide site or 5.97 ± 1.96 substitutions
per genome replication event) as compared with less frequently detected strains, GII.P21
(1.53 × 10−4 or 1.15 substitutions per genome replication event) and GII.7 (2.21 × 10−5 or
0.17 substitutions per genome replication event).
Recently, single-cycle viral replication of a Norwalk virus infectious cDNA clone
transfected into human embryonic kidney cells yielded a mutation rate estimate of 1.5
× 10−4 s/n/c [311]. Interestingly, a large fraction of spontaneous mutations constituted
U-to-C and A-to-G substitutions occurring as bouts of mutations in the same RNA molecule.
Such sequence changes are characteristic of adenosine to inosine editing (inosines subse-
quently base-pair with cytosines) by double-strand RNA-dependent adenosine deaminases
(ADARs) [312], suggesting that host-driven extrinsic norovirus hypermutation acting on
double-stranded replication intermediates may be a source of norovirus diversity compara-
ble to intrinsic viral RdRp fidelity. In depth analysis of spontaneous mutations in clinical
GII.4 samples has supported the hypothesis that hypermutation may reflect a relevant
mutational process in noroviruses [311].
11.2. Evolutionary Rates of Human Noroviruses
Early bioinformatics analysis of published ORF2 sequence data revealed strain depen-
dent differences in norovirus evolutionary rates, estimating 1.7-fold higher average rates of
evolution within GII.4 capsid sequences (3.9 × 10−3 nucleotide substitutions per site per
year (n/s/y)) than other noroviruses (GII.3, GII.3[Pb], GII.7 with 1.9 × 10−3, 2.4 × 10−3,
and 2.3× 10−3 n/s/y, respectively) [310]. Higher ratios of nonsynonymous to synonymous
amino acid changes in GII.4 capsids were held to indicate that GII.4 strains experience
faster rates of antigenic drift than other norovirus strains as a probable consequence of their
higher RdRp mutation rates [310]. Nonsynonymous mutations for norovirus GII.4 and
all other analysed genotypes (albeit at lower numbers) were shown to cluster to common
structural surface-exposed residues of the hypervariable P2 capsid domain, correspond-
ing to known HBGA-binding targets and hypervariable GII.4 “evolution hotspots” [313],
suggesting that these sites are likely to be subject to immune-driven selection [310].
Other long-term evolutionary analyses of archival norovirus sequences have calcu-
lated similar population-level evolutionary rates for GII.4 VP1 capsid sequences (4.3 ×
10−3 n/s/y) and have identified preferential sites for evolution under positive selection
to be located in the VP1 shell domain as well as P2 [314,315]. However, in contrast to
previous observations, evolutionary rates of various non-GII.4 genotypes, for example,
GII.3 VP1 (4.16 × 10−3 n/s/y) [181], GII.2[P2] (1.75 × 10−3 n/s/y), and GII.2[P16] (2.37 ×
10−3 n/s/y) [316] have been estimated to be close to those of GII.4 strains. Differences in
mutation rates may provide higher diversity at a given time (e.g., after a recombination
event) and so confer an advantage to GII.4 strains; however, they seem to have a limited
impact on overall norovirus evolutionary rates. Strain-dependent differences of norovirus
evolutionary patterns are, thus, not entirely attributable to differences in viral RdRp fidelity
and remain to be fully elucidated.
Full-genome deep sequencing analyses have revealed that evolutionary rates are
not uniform across the norovirus genome, with surface- and immune-exposed regions
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experiencing more variation than less malleable sections. Correspondingly, ORF2 (VP1) and
ORF3 (VP2)-specific rates are typically higher than those reported for ORF1 (NS). Within
ORF1, regions encoding NS1/2 and NS4 have been shown to exhibit the highest levels
of change [317,318]. Overall norovirus evolutionary dynamics at inter-host population
levels may differ from intra-host dynamics where, subsequent to transmission typically
characterised by a strong genetic bottleneck, evolutionary rates fluctuate by several orders
of magnitude dependent on the host immune status [231,232,236] (as described in chapter
1.6.6).
11.3. Impact of Human Norovirus Diversification via Point Mutation Accumulation
The emergence of GII.4 variants is commonly ascribed to the accumulation of novel
VP1 GII.4 amino acid mutations (linear evolution with intermediate periods of stasis),
while non-GII.4 genotypes experience limited changes and can persist for decades with
minimal VP1 modification as so-called static genotypes [181,237,315,319].
The emergence of both GII.4 and non-GII.4 viruses has been linked to changes in
the viral RdRp, highlighting it, and potentially other nonstructural proteins, as drivers of
norovirus evolution. Thus, the emergence of certain GII.4 variants (since their establishment
as prevalent genotype in the mid-1990s) has been associated with mutations in the GII.4
RdRp gene [320] or acquisition of a new viral polymerase via recombination (the genetic
diversity of GII.4 variants due to recombination is discussed in chapter 2.3) [237,321].
Both the predominance of re-emerging (2016–2017) [316,322] recombinant GII.2 [P16]
viruses [316,319] and GII.17[P17] viruses between 2013 and 2015 [323] have been putatively
associated to substitutions in the viral RdRp. Notably, single HuNoV RdRp point mutations
have been experimentally demonstrated to affect replication kinetics [310].
Thus, norovirus diversification and emergence are associated (in varying measure)
with changes to two regions of the norovirus genome, nonstructural protein-encoding
ORF1 and VP1-encoding ORF2.
11.4. Murine Norovirus Evolution via Point Mutation Accumulation
In vitro mutation rates have been inferred for representative genome regions of MNV
isolate MNV1-CW1 [324]. Mutation rates were shown to not significantly differ between
regions encompassing partial coding sequences for NS1/2, NS5, NS6, and NS7 within
ORF1, where they were within the same range as those reported for various HuNoV
strains, but were estimated to be at least one order of magnitude higher for partial ORF2,
-3, and -4 sequences [324]. Interestingly, the existence of defective RNAs or defective
interfering particles, commonly associated with the population dynamics of error-prone
virus replication [325], was indicated by diverging infectious norovirus virus titres and
genomic copy values determined during MNV serial passaging [324].
Highlighting the importance of point mutation as an evolutionary mechanism for
noroviruses, a single point mutation in NS1/2 (changing aspartic acid to glutamic acid)
has been shown to dramatically alter the biological behaviour of a MNV, rendering non-
persistent MNV1-CW3 persistent and causing an increased growth of CW3 in the proximal
colon, a tissue reservoir of MNV persistence [91,165]. Furthermore, a single amino acid
substitution in VP1 has been shown to be sufficient for MNV attenuation (or the reversion
thereof) in vivo [326]. Other in vivo assays have shown that single point mutations mod-
ulating MNV RdRp fidelity may affect MNV pathogenesis; Arias et al. demonstrated a
high-fidelity MNV-3 NS7 active-site mutant to exhibit delayed replication in vivo (but not
in vitro) and reduced transmission between hosts, suggesting that the generation of suffi-
cient genetic diversity (via a low-fidelity RdRp) may be linked to efficient intra-host virus
transmission [327]. Conversely, artificially increased mutagenesis above the inherently
high mutation rates of noroviruses has been shown to lead to extinction of MNV popula-
tions [293], highlighting the norovirus RdRp as an important target for the development of
anti-noroviral therapies.
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11.5. Norovirus Recombination
Norovirus recombination can create chimeric viruses to generate new recombinants
and further contribute to norovirus strain diversification by combining and modifying
existing mutational profiles. Intragenotypic recombination has long been postulated to be
a driving force of GII.4 noroviruses. Increasingly, emergence and re-emergence of different
intragenotype recombinants have been reported [182,328,329]. The subject of norovirus
recombination was recently reviewed by our group; we refer to our 2018 review [182] for
further information.
12. Model Systems to Study Norovirus Biology
12.1. In Vivo Model Systems for Human Noroviruses
Early volunteer challenge studies and epidemiological observations of HuNoVs in
their natural hosts have yielded important in vivo data to further the understanding of
HuNoV infections [55,134,271]. However, the interpretation of results from such studies
may be complicated by small sample sizes, variations in susceptibility to infection, previous
history of exposure, and cross-reactivity of antibodies. In addition, volunteer studies may
pose potential health risks to participants. Thus, a robust HuNoV animal model has long
been sought.
Various non-human primates have been tested as HuNoV infection models [330].
While neither baboons, common marmosets, cotton top tamarins, nor cynomolgus seem
susceptible to HuNoV infection [331], rhesus macaques and chimpanzees produce serum
antibodies and shed virus upon oral HuNoV infection but do not develop clinical symp-
toms [331–333]; only infection of pigtail macaques has been shown to result in typical
clinical illness including vomiting, thus, potentially presenting a model to study the emetic
response to HuNoVs [334].
Large animal models for symptomatic HuNoV infection include gnotobiotic pigs
and calves. Infection of gnotobiotic piglets with a GII.4 HuNoV results in mild diarrhoea,
faecal shedding of viral RNA, expression of viral RNA in intestinal enterocytes and extra-
intestinal lymphoid tissues, and seroconversion [335,336]. Prolonged HuNoV infections
and viral dissemination beyond the intestine have been observed in gnotobiotic pigs
with a severe combined immunodeficiency phenotype [337]. Gnotobiotic piglets provide
a useful experimental model as the pig intestine anatomy resembles that of humans
and protection from disease provides a valuable readout in vaccine trials and testing of
therapeutics [338,339]. Gnotobiotic calves infected orally with HuNoV develop diarrhoea
associated with intestinal damage and faecal viral shedding for up to six days, as well as
local and systemic immune responses [340].
Double knockout recombination activation gene (Rag−/−) and common gamma chain
(γc−/−) deficient BALB/c mice support subclinical HuNoV GII.4 replication upon infection
via the intraperitoneal route [341]. The model has been used to assess the anti-HuNoV
activities of antiviral compounds [342]. However, since these mice cannot be infected
orally and lack both gut-associated lymphoid tissues and the ability to produce numerous
cytokines and mature B and T cells, the model cannot recapitulate typical HuNoV infection.
Recently, multiple HuNoV GI and GII strains were shown to replicate to high titres in
cells of both the hematopoietic lineage and the intestine of zebrafish larvae (Danio rerio)
following yolk inoculation (larval food reserve) [273]. Yielding over three orders of magni-
tude (3log10) increases in GII.4 viral RNA copies, zebrafish larvae were shown to constitute
a simple and robust in vivo HuNoV replication model and were also demonstrated to be
suited to antiviral studies.
12.2. Human Norovirus Tropism and In Vitro Culture of Human Noroviruses
In lieu of a stable HuNoV culture system, HuNoV in vitro assays were, until very re-
cently, conducted using the Norwalk virus replicon [102] and/or virus-like particles (VLPs).
The Norwalk virus RNA replicon consists of an intact ORF1 and ORF3, and an ORF2
disrupted by a neomycin gene engineered into the VP1-encoding region (thus blocking
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expression of intact VP1). Self-replicating and stably expressed following transfection into
cell lines of human (Huh-7) or hamster (BHK21) origin, the replicon has proven useful for
the study of HuNoV genome replication and screening of antiviral compounds [295,343].
The RNA replicon is complemented by VLP systems, in which expression of capsid pro-
tein VP1 results in the self-assembly of recombinant VLPs that are morphologically and
antigenically indistinguishable from native HuNoV virions and consequently represent
useful tools to study physical virion properties, antibody responses, and attachment factor
interactions [39].
Notwithstanding the utility of these two systems, the fact that the understanding of
HuNoV biology has lagged behind that of other positive strand RNA viruses has been,
in great part, due to the difficulties historically associated with robust in vitro HuNoV
propagation [344,345]. In turn, issues with HuNoV cell culture stem from the uncertainties
still surrounding HuNoV tropism and the lack of a known (proteinaceous) entry receptor
(see above). Recent data support a dual cell tropism of epithelial cells and nonepithelial
cells of hematopoietic origin both in vivo [346] and in vitro [347] and illustrate a complex
interplay with the host microbiome [79,348].
Currently, two different HuNoV cell culture systems successfully capitalise on this
dual tropism. The development of the in vitro BJAB human B cell line demonstrated
that HuNoV (and MNV) can either infect B cells directly or in a coculture system in
which the virus must cross a confluent epithelial monolayer to access underlying B cells.
Productive GII.4 HuNoV infection of B cells required the presence of the HGBA-expressing
commensal bacteria (or free synthetic HBGA), identifying them as a stimulatory cofactor for
bridging norovirus attachment to and infection of B cells [108,348]. This and other available
data directed the development of a working model for norovirus intestinal infection,
whereby noroviruses bind to specific glycans expressed on the surface of members of
the gut microbiota and/or enterocytes, and then are transcytosed across the polarised
intestinal epithelial barrier to gain access to their target immune cells [109,349]. Notably,
this model provides an explanation for how noroviruses may achieve co-infection of
host cells in conditions when the number of cells far outweighs that of virions; multiple
genetically distinct virions can be effectively concentrated by binding to the surface of a
single bacterium, thereby increasing the opportunity for co-infection [350,351]. While the
technical simplicity and use of a commonly used cell line are strengths of the BJAB assay,
current drawbacks are the modest level of viral replication and varying reproducibility.
In a technically more complicated approach, but with more robust infection levels
overall, cultivation of multiple HuNoV strains has recently been demonstrated in stem
cell derived, human intestinal enteroid (HIE) cultures (epithelial mini guts) which re-
capitulate the multicellular, physiologically active human intestinal epithelium [73,352].
Grown from single multipotent stem cells of the human intestinal crypts (isolated from
endoscopic biopsies), HIEs can be maintained continuously as three-dimensional cultures.
Differentiation into distinct mature cell types present in the epithelium, such as absorp-
tive enterocytes, multiple secretory cells (Paneth cells, goblet cells, enteroendocrine cells,
and tuft cells), and the M cells of Peyer’s patches can be achieved by modifying culture
conditions [353,354]. Propagation (and limited passaging) of HuNoVs in enterocytes of
differentiated HIEs (seeded into monolayers) has been shown to be dependent on HBGA
expression in a strain-dependent manner (secretor-negative HIEs are permissive to GII.3,
but not GII.4 replication). Bile acids have been shown to assist productive infection of
certain strains (GI.1, GII.3, and GII.17) [47], but bile is not necessary for cultivation of
HuNoV GII.4/Sydney and may also be dispensed with when specific media are used [355].
The expense and complexity of the HIE system, relatively low sensitivity of the cultures
to infection, issues with sustained passaging, and the unresolved basis for strain specific
replication requirements remain challenges faced in the ongoing enhancement of HuNoV
HIE cultures [352].
Different in vivo and in vitro HuNoV assays have all provided invaluable tools to
dissect the norovirus life cycle. However, there is still a lack of detailed understanding of
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norovirus replication and significant questions remain unanswered due to the technical
limitations of many of these experimental systems. Experimental models of HuNoV
infection are discussed in detail in the 2019 review by Todd and Tripp [330].
12.3. The Murine Norovirus—An In Vivo and In Vitro Human Norovirus Surrogate
The genetically and biologically closely related murine norovirus (MNV) combines
the advantages of easy in vivo infection of a cost-effective, genetically tractable, bona-fide
native host [16], efficient and robust in vitro culture systems [167,356], and availability of
tools for genetic manipulation (including both DNA- and RNA-based reverse genetics
systems) [163,357,358]. Caveats to the model include differences between HuNoV and
MNV carbohydrate attachment factors and proteinaceous receptors (see above), the fact
that HuNoVs replicate in intestinal enterocytes, a cellular tropism that MNV does not
seem to share, and the typically asymptomatic nature of MNV infections in wild-type mice.
In vivo MNV infections of adult immunocompetent and immunocompromised mice as
well as those of neonatal mice are described above. The adult in vivo models have long
yielded valuable information concerning the biology of a norovirus in its natural host [167].
The newly described model of norovirus diarrhoea in which key clinical features of HuNoV
disease are mirrored in MNV-infected neonatal mice will open up new avenues of research
and the finding that disease severity is regulated by viral genetics (MNV-3 and MNV-CR6
cause a reduced incidence of diarrhoea relative to MNV-1) will facilitate identification of
viral virulence determinants [169].
Until very recently, MNVs were the only cultivable noroviruses, replicating efficiently
and to high titres in cultured bone marrow-derived murine macrophages (RAW264.7
cells) [167,356] and murine-derived microglial cells (BV-2 cells) [359] as well as B cells
(M12 and WEHI-231), where peak titres are reached one day later than in RAW264.7
macrophages [348].
13. Conclusions
The fact that the understanding of HuNoV biology lags behind that of other posi-
tive strand RNA viruses, is, in great part, due to the difficulties historically associated
with robust in vitro HuNoV propagation. In recent years, novel model systems have
provided new opportunities for the study of HuNoVs and previous knowledge gaps are
progressively being filled. Recent advances in the field comprise an updated classifica-
tion system [10], the description of alternative virus-like protein (VLP) morphologies [48],
and the further elucidation of the functions of both structural and nonstructural viral
proteins and their roles in the norovirus replicative cycle [36,52,92,101]. Important mile-
stones include new insights into cell tropism [40,44], host- and microbial attachment factors
and receptors [43,59–61,71–73,79,360], interactions with the cellular translational appara-
tus [80,83,84], and viral egress from cells [110]. Noroviruses have been detected in previ-
ously unrecognised host species [18,19]; detection itself is facilitated by the novel analytical
techniques that increasingly supplement established molecular methods [259,261–263,265].
New potential HuNoV transmission routes and/or viral reservoirs have been postu-
lated [223,230,233]. Recent in vivo and in vitro findings have added to the understanding
of host immunity in response to norovirus infection [272–274]. While neither approved
vaccines nor small molecule treatments are yet available, vaccine development has pro-
gressed to preclinical and even clinical trial testing of candidates [281,306–308] and ongoing
development of therapeutic agents includes promising direct-acting small molecules and
host-factor drugs [145,292,296,302]. Many of these discoveries have been facilitated by
novel in vitro and in vivo culture systems that have inspired fascinating new avenues of
norovirus research.
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